Cargando…
Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system
BACKGROUND: Current investigations suggest that the Base Excision Repair (BER) system may change DNA repair capacity and affect clinical gastric cancer progression such as overall survival. However, the prognostic value of BER system members in gastric cancer remains unclear. METHODS: We explored th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750847/ https://www.ncbi.nlm.nih.gov/pubmed/31571995 http://dx.doi.org/10.2147/CMAR.S217375 |
_version_ | 1783452527522480128 |
---|---|
author | Ni, Fubiao Tang, Hengjie Wang, Cheng Wang, Zixiang Yu, Fangyi Chen, Bicheng Sun, Linxiao |
author_facet | Ni, Fubiao Tang, Hengjie Wang, Cheng Wang, Zixiang Yu, Fangyi Chen, Bicheng Sun, Linxiao |
author_sort | Ni, Fubiao |
collection | PubMed |
description | BACKGROUND: Current investigations suggest that the Base Excision Repair (BER) system may change DNA repair capacity and affect clinical gastric cancer progression such as overall survival. However, the prognostic value of BER system members in gastric cancer remains unclear. METHODS: We explored the prognostic correlation between 7 individual BER genes, including uracil-DNA glycosylase (UNG), Single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1), Methyl-CpG binding domain 4 (MBD4), thymine DNA glycosylase (TDG), 8-oxoguanine DNA glycosylase (OGG1), MutY DNA glycosylase (MUTYH) and Nei like DNA glycosylase 1 (NEIL1), expression and overall survival (OS) in different clinical data, such as Lauren classification, pathological stages, human epidermal growth factor receptor-2 (HER2) expression status, treatment strategy, gender and differentiation degree in gastric cancer patients, using Kaplan-Meier plotter (KM plotter) online database. Based on the bioinformatics analysis, we utilized Berzosertib (VE-822) to inhibit DNA damage repair in cancer cells compared to solvent control group via real-time cellular analysis (RTCA), flow cytometry, colony formation and migration assay. Finally, we utilized reverse transcription-polymerase chain reaction (RT-PCR) to confirm the expression of BER members between normal and two gastric cancer cells or solvent and VE-822 treated groups. RESULTS: Our work revealed that high UNG mRNA expression was correlated with high overall survival probability; however, high SMUG1, MBD4, TDG, OGG1, MUTYH and NEIL1 mRNA expression showed relatively low overall survival probability in all GC patients. Additionally, UNG was associated with high overall survival probability in intestinal and diffuse types, but SMUG1 and NEIL1 showed opposite results. Further, VE-822 pharmacological experiment suggested that inhibition of DNA damage repair suppressed gastric cancer cells’ proliferation and migration ability via inducing apoptosis. Further, real-time polymerase chain reaction results proposed the inhibition of gastric cancer cells by VE-822 may be through UNG, MUTYH and OGG-1 of BER system. CONCLUSION: We comprehensively analyze the prognostic value of the BER system (UNG, SMUG1, MBD4, TDG, OGG1, MUTYH and NEIL1) based on bioinformatics analysis and experimental confirmation. BER members are associated with distinctive prognostic significance and maybe new valuable prognostic indicators in gastric cancer. |
format | Online Article Text |
id | pubmed-6750847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67508472019-09-30 Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system Ni, Fubiao Tang, Hengjie Wang, Cheng Wang, Zixiang Yu, Fangyi Chen, Bicheng Sun, Linxiao Cancer Manag Res Original Research BACKGROUND: Current investigations suggest that the Base Excision Repair (BER) system may change DNA repair capacity and affect clinical gastric cancer progression such as overall survival. However, the prognostic value of BER system members in gastric cancer remains unclear. METHODS: We explored the prognostic correlation between 7 individual BER genes, including uracil-DNA glycosylase (UNG), Single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1), Methyl-CpG binding domain 4 (MBD4), thymine DNA glycosylase (TDG), 8-oxoguanine DNA glycosylase (OGG1), MutY DNA glycosylase (MUTYH) and Nei like DNA glycosylase 1 (NEIL1), expression and overall survival (OS) in different clinical data, such as Lauren classification, pathological stages, human epidermal growth factor receptor-2 (HER2) expression status, treatment strategy, gender and differentiation degree in gastric cancer patients, using Kaplan-Meier plotter (KM plotter) online database. Based on the bioinformatics analysis, we utilized Berzosertib (VE-822) to inhibit DNA damage repair in cancer cells compared to solvent control group via real-time cellular analysis (RTCA), flow cytometry, colony formation and migration assay. Finally, we utilized reverse transcription-polymerase chain reaction (RT-PCR) to confirm the expression of BER members between normal and two gastric cancer cells or solvent and VE-822 treated groups. RESULTS: Our work revealed that high UNG mRNA expression was correlated with high overall survival probability; however, high SMUG1, MBD4, TDG, OGG1, MUTYH and NEIL1 mRNA expression showed relatively low overall survival probability in all GC patients. Additionally, UNG was associated with high overall survival probability in intestinal and diffuse types, but SMUG1 and NEIL1 showed opposite results. Further, VE-822 pharmacological experiment suggested that inhibition of DNA damage repair suppressed gastric cancer cells’ proliferation and migration ability via inducing apoptosis. Further, real-time polymerase chain reaction results proposed the inhibition of gastric cancer cells by VE-822 may be through UNG, MUTYH and OGG-1 of BER system. CONCLUSION: We comprehensively analyze the prognostic value of the BER system (UNG, SMUG1, MBD4, TDG, OGG1, MUTYH and NEIL1) based on bioinformatics analysis and experimental confirmation. BER members are associated with distinctive prognostic significance and maybe new valuable prognostic indicators in gastric cancer. Dove 2019-09-13 /pmc/articles/PMC6750847/ /pubmed/31571995 http://dx.doi.org/10.2147/CMAR.S217375 Text en © 2019 Ni et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ni, Fubiao Tang, Hengjie Wang, Cheng Wang, Zixiang Yu, Fangyi Chen, Bicheng Sun, Linxiao Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title | Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title_full | Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title_fullStr | Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title_full_unstemmed | Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title_short | Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system |
title_sort | berzosertib (ve-822) inhibits gastric cancer cell proliferation via base excision repair system |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750847/ https://www.ncbi.nlm.nih.gov/pubmed/31571995 http://dx.doi.org/10.2147/CMAR.S217375 |
work_keys_str_mv | AT nifubiao berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT tanghengjie berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT wangcheng berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT wangzixiang berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT yufangyi berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT chenbicheng berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem AT sunlinxiao berzosertibve822inhibitsgastriccancercellproliferationviabaseexcisionrepairsystem |